{
  "ptid_time": "941_S_6068_2018-08-17",
  "img_path": "/data/qiuhui/data/adni/images/941_S_6068/2018-08-17/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 31,523 mm³, 18.2% below the reference mean. With a Z-score of -0.44 (33.2th percentile), this represents normal volume ; hippocampal volume measures 5,971 mm³, 21.0% below the reference mean. With a Z-score of -2.05 (2.0th percentile), this represents significant atrophy; whole brain volume measures 1,009,940 mm³, 6.4% below the reference mean. With a Z-score of -0.84 (20.2th percentile), this represents normal volume ; entorhinal cortex volume measures 2,851 mm³, 30.5% below the reference mean. With a Z-score of -2.07 (1.9th percentile), this represents significant atrophy; fusiform gyrus volume measures 14,457 mm³, 23.3% below the reference mean. With a Z-score of -1.98 (2.4th percentile), this represents moderate atrophy; middle temporal gyrus volume measures 17,451 mm³, 18.2% below the reference mean. With a Z-score of -1.64 (5.1th percentile), this represents moderate atrophy. ",
  "text_data": "Age is 76.7 years. Gender is Male. Education: 12 years. MMSE: 25.0. MoCA: 19.0. Logical Memory: 0.0. APOEε4 alleles: 1.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The patient shows significant atrophy in the hippocampus and entorhinal cortex, along with moderate atrophy in the fusiform gyrus and middle temporal gyrus—key regions affected in Alzheimer’s disease. Cognitive testing (MoCA 19, MMSE 25) indicates mild impairment, and the presence of one APOE4 allele further supports increased AD risk.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely due to underlying Alzheimer’s pathology).  \n\n**Confidence:** **High** (due to clear structural atrophy in AD-vulnerable regions and concordant cognitive deficits).  \n\n*Note:* Progression to dementia is likely if neurodegeneration continues, but current cognitive deficits do not yet meet dementia criteria (e.g., preserved functional independence). Biomarkers (e.g., CSF amyloid/tau) could further refine the diagnosis.",
  "timestamp": "2025-07-26T17:45:37.459127"
}